



Correction to: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features

Katherine A. Lyseng-Williamson¹

Published online: 12 September 2019
© Springer Nature 2019

Correction to: Clinical Drug Investigation
<https://doi.org/10.1007/s40261-019-00826-0>

The article *Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features*, written by KA Lyseng-Williamson, was originally published Online First without open access. After publication in *volume 39, issue 8, pages 805–819, Springer Healthcare IME* requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by an independent educational grant from *Novo Nordisk A/S*. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use,

duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40261-019-00826-0>.

✉ Katherine A. Lyseng-Williamson
DEcorrespondence@springer.com

¹ Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand